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Abstract: Selenium is an essential trace element. Although this chalcogen forms a wide variety of
compounds, there are surprisingly few small-molecule organic selenium compounds (OSeCs) in
biology. Besides its more prominent relative selenocysteine (SeCys), the amino acid selenomethionine
(SeMet) is one example. SeMet is synthesized in plants and some fungi and, via nutrition, finds its way
into mammalian cells. In contrast to its sulfur analog methionine (Met), SeMet is extraordinarily redox
active under physiological conditions and via its catalytic selenide (RSeR’)/selenoxide (RSe(O)R’)
couple provides protection against reactive oxygen species (ROS) and other possibly harmful oxidants.
In contrast to SeCys, which is incorporated via an eloquent ribosomal mechanism, SeMet can
enter such biomolecules by simply replacing proteinogenic Met. Interestingly, eukaryotes, such as
yeast and mammals, also metabolize SeMet to a small family of reactive selenium species (RSeS).
Together, SeMet, proteins containing SeMet and metabolites of SeMet form a powerful triad of
redox-active metabolites with a plethora of biological implications. In any case, SeMet and its family
of natural RSeS provide plenty of opportunities for studies in the fields of nutrition, aging, health
and redox biology.
Keywords: aging; selenium; selenomethionine (SeMet); reactive selenium species (RSeS)
1. Introduction
Selenium is an essential trace element in humans [1]. Since its discovery by Joens Jacob
Berzelius (1779–1848) in 1817, the element has fascinated chemists and biochemists alike.
During the last five decades, hundreds of organic selenium compounds (OSeCs) have been
produced to mimic the unique biological activity of selenium enzymes, such as the human
glutathione peroxideases (GPx), human thioredoxin reductase (TR) and iodothyronine deio-
dinase (ID) [2,3]. Notably, nature itself produces only a few organic selenium compounds
on its own. Besides the rather prominent amino acid SeCys and intermediates involved in
its biosynthesis from inorganic selenite SeO32− and subsequent metabolic degradation to
methylselenide CH3SeH, dimethylselenide (CH3)2Se and dimethylselenonium (CH3)3Se+,
such natural small-molecule selenides are rare. The few notable exceptions found Nature
include compounds such as the histidine derivative and ergothionine analog selenoneine
present in tuna fish and inorganic selenocyanate (SeCN−) in the green freshwater algae
Chlorella vulgaris [4,5].
Indeed, SeCys dominates most discussions of selenium in proteins and enzymes,
which is hardly surprising, as most of the roughly 25 selenium proteins identified in
humans to date contain one or more SeCys residues [6]. In fact, SeCys is often referred
to as the 21st amino acid, and its insertion into human proteins is controlled tightly via
specific SeCys insertion sequences (SECISs). In contrast, the other natural selenium amino
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acid, selenomethionine (SeMet), occupies a more exotic niche in biology, although SeMet
combines some truly amazing and exciting features worth discussing. SeMet, for instance,
is produced in plants and fungi and in many organisms literally sneaks into proteins and
enzymes in place of its sulfur analog methionine (Met), thereby endowing these proteins
with extra redox activity [7]. SeMet on its own is also highly redox active, similar to the
flagship antioxidant ascorbic acid, and in yeast is a fine source of numerous, equally active
metabolites, such as selenohomocysteine, selenoglutathione, γ-glutamylselenocysteine and
Se-adenosylselenohomocysteine. In humans, SeMet is absorbed via intestinal transport
channels and subsequently enters the methionine pool, where it is stored and conse-
quently recruited from to become integrated into proteins [8]. Once in the liver, SeMet
follows the methionine cycle and trans-selenation pathways to produce S-adenosyl SeMet,
adenosyl selenohomocysteine, homocysteine, selenocystathionine and SeCys, as shown in
Figures 1 and 2 [9].
Figure 1. Biosynthesis of SeMet in plants involves the uptake of SeO42− via SO42− transporters and its interaction with
ATP to produce adenosylphosphoselenate, which is reduced to SeO32− by adenosylphosphosulfate reductase. SeO32−,
either absorbed via PO43− transporters or reduced from SeO42−, is further reduced to selenide by GSH via intermediates
such as selenodiglutathione and glutathioneselenol. The interaction of selenide with O-acetylserine results ultimately
in the formation of SeCys. Interaction of SeCys with homoserine in the presence of cystathionine synthase generates
selenocystathionine which is cleaved enzymatically by cystathionine lyase to selenohomocysteine, pyruvate and ammonia.
This is followed by the formation of SeMet from selenohomocysteine via methionine synthase.
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Figure 2. Structures of some of the metabolites of SeMet found in selenium-enriched yeast.
As part of this minireview, we shall therefore provide some essential information
about this fascinating and in many aspects unique proteinogenic amino acid, from its
biosynthesis in plants and metabolism in yeast to its ability to replace Met in proteins and
its role as a food supplement. From the onset, we would like to emphasize that we have
focused on some of the more recent and exciting discoveries in this field and therefore shall
refer to the existing literature for more basic information [10–13].
2. Biosynthesis of SeMet in Plants
Higher organisms, such as mammals and humans, are unable to synthesize SeMet.
This task is left to plants and fungi, including yeast (Saccharomyces cerevisiae) and a few
edible mushrooms, such as the Shiitake (Lentinula edodes) and King Bolete (Boletus edulis)
mushrooms [14,15]. Plants absorb SeO32− and SeO42− from the soil and convert these
inorganic salts to different organic forms of selenium following a sequence of biochemical
events, as shown in Figure 1. The absorption of SeO42− and SeO32− in plants is con-
trolled tightly and involves certain transporters, such as sulfate (SO42−) and phosphate
(PO43−) transporters in rice and wheat, respectively [16–18]. SeO42− interacts with ATP
in the presence of ATP sulfurylase (ATPS) to produce adenosylphosphoselenate, which is
subsequently reduced by adenosine phosphosulfate reductase to SeO32− consuming the
reduced form of glutathione (GSH) as the electron donor [19]. SeO32−, either absorbed via
PO43− transporters or reduced from SeO42−, interacts spontaneously with GSH to produce
selenodiglutathione (GSSeSG), which is subsequently reduced by GSH reductase (GSR)
to generate glutathioneselenol (GSeH), which is again reduced by GSR in the presence of
GSH to form hydrogen selenide (H2Se) [20]. The interaction of H2Se with O-acetyl serine
in the presence of cysteine synthase results in the formation of SeCys [21].
SeMet is synthesized from SeCys in several steps. The α-amino acid homoserine
interacts with SeCys to produce a selenocystathionine adduct, which is subsequently
hydrolyzed to selenohomocysteine, pyruvate and ammonia, as illustrated in Figure 1.
Selenohomocysteine is then converted to SeMet by methionine synthase [22]. There are
two types of methionine synthase, i.e., cobalamine-dependent methionine synthase (E.C.
2.1.1.13) and cobalamine-independent methionine synthase (E.C. 2.1.1.14). The main
function of both methionine synthases involves the catalysis of the transfer of functional
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methyl groups from 5-methyltetrahydrofolate to the thiol moiety of (seleno)homocysteine
to produce tetrahydrofolate and (Se)Met [23]. Among the various plant species, cereals and
forage crops primarily convert Se to SeMet, which they subsequently store. These plants
also incorporate SeMet into proteins in lieu of Met, as the tRNAMet responsible for the
incorporation of Met does not distinguish between Met and SeMet, an issue of the blatant
hijacking of a sulfur pathway by selenium we shall discuss on several occasions during
this review. Indeed, the production of SeMet in plants is not linked to any specific stimuli
or requirements and is mainly running side by side to the synthesis of Met [24]. Whether
Met or SeMet are synthesized then depends mostly on the amount of selenium available in
the soil and not on any sophisticated design or game plan(t).
Yeast as a eukaryote can reduce SeO32− and synthesize SeMet following the footsteps
of plants, although it also produces other selenium species, including elemental red sele-
nium Se±0, often in form of nanoparticles, a metabolic detoxification pathway actually also
common in many bacteria and fungi, including Lactobacillus plantarum, Escherichia coli and
S. cerevisiae [25]. Compared to plants and yeasts, mammals are unable to synthesize SeMet,
as they turn SeO32− into GSSeSG, H2Se and SeCys, yet do not process SeCys to SeMet [9].
3. SeMet in Yeast
The nonspecific and accidental biosynthesis of SeMet in yeast from SeO42− or SeO32−
follows the one in plants [26]. Interestingly, yeast is also able to take up SeMet quite readily
from external sources. Once inside the yeast cell, SeMet plays several rather special roles.
As some metabolic enzymes are unable to distinguish between Met and SeMet, just as in
plants, this enables SeMet to take on the false identity of its sulfur analog and literally to
sneak into proteins in place of Met [27,28]. It is important to mention that the amount of
total Met in yeast (S. cerevisiae) is very low, i.e., around 0.75%, based on dry weight [29].
The extent to which Met is replaced by SeMet depends upon the conditions in which yeast
is cultivated. Under standard industrial conditions, 30–45% of Met can be substituted by
SeMet, while controlled laboratory-based experimental conditions may yield an amazing
>98% substitution of SeMet for Met in the entire protein pool, as found, for example, in a
wild-type yeast [30,31].
Furthermore, in such fungi, SeMet can requisite the machinery responsible for chang-
ing Met into many other natural sulfur compounds, and this results in the production of a
plethora of interesting selenium compounds, some of which are shown in Figure 2.
Liquid chromatography coupled with orbitrap mass spectrometry, for example, has
been utilized to hunt for such OSeCs in S. cerevisiae treated with SeO32−, SeO42− and
SeMet [32]. The highest amount of Se inside cells has been observed in yeast cells treated
with SeMet as compared to SeO32− or SeO42−. Treatment of yeast with SeMet significantly
enhances the intracellular level of SeMet in yeast in less than 15 min, confirming a surpris-
ingly fast and comprehensive uptake of SeMet by these cells. SeO32− and SeO42− are also
taken up and processed in yeast to organic selenides, such as selenohomocysteine (SeHcy),
gamma-glutamylselenocysteine, selenoglutathione (GSeH), 5′-methylselenoadenosine, Se-
adenosylhomocysteine (SeAHcy) and Se-adenosylmethionine (SeAM), in addition to ele-
mental selenium as mentioned before.
Notably, while yeast can synthesize SeMet following the sulfur pathway, it is not the
preferred selenium compound produced in S. cerevisiae. Popular notions that selenium-
enriched yeast contains mostly SeMet therefore are not entirely correct. Among the various
selenium compounds found in this fungus, the rather exotic SeAHcy shown in Figure 2
dominates the field, as it amounts to around 70% of total selenium content [32]. In contrast,
the individual shares of other selenium compounds are below 10%. Interestingly, SeAM is
also formed in yeast and can take on some of the roles of its more popular sulfur analog,
S-adenosylmethionine (SAM), which acts as a methyl donor in various eukaryotic cells.
SeAM serves, for example, as a precursor in the synthesis of SeAHcy and is also involved
in the methylation of lipids, proteins, nucleic acids and various secondary metabolites.
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Furthermore, methyltransferases are able to transfer methyl groups from SeAM to different
nucleic acids, i.e., ribosomal and transfer RNAs and even DNA [33].
SeAHcy is hydrolyzed by S-adenosylhomocysteine hydrolase to adenosine and SeHcy,
as shown in Figure 2. Unlike methionyl-tRNA synthetase, which does not discriminate
between Met and SeMet, S-adenosylhomocysteine hydrolase actually demonstrates a slight
discrimination, as its hydrolase activity against SeAHcy is relatively low as compared to its
activity against S-adenosylhomocysteine. This also explains why SeHcy is found in yeast in
relatively small amounts of around 8.5% of selenium compounds, despite the presence of
excessive amounts of SeAHcy, for instance in yeast cells treated with SeMet. The presence
of 5′-methylselenoadenosine, a rather exceptional selenide shown in Figure 2, in such cells
treated with SeMet has been reported [34] Considering the overall situation in yeast, SeMet
follows the same metabolic pathways as Met, although the distribution of selenium species
differs significantly from that of sulfur analogs. In any case, neither SeMet nor SeHcy is the
main selenium compound in S. cerevisiae, with more exotic substances such as SeAM and
chiefly SeAHcy dominating the field.
4. Redox Activity and Catalysis of SeMet
As mentioned already, many organisms are unable to distinguish between SeMet and
Met and therefore tend to accept SeMet in many physiological processes in place of Met.
This has notable consequences, as SeMet tends to be more reactive than Met and often acts
as a redox cycler and catalyst. This strong antioxidant potential associated with selenium is
found for SeMet as a free amino acid, for SeMet in proteins and enzymes and, notably, also
for a range of other SeMet precursors and follow-on products containing the same selenide
RSeR’ motif [35]. Then again, one may mention that the selenide RSeR’ generally is less
reactive compared to the selenol(ate) RSeH or RSe−. Nonetheless, the literature is rich in
examples underlining the biological redox activity of SeMet.
In simple assays, SeMet protects dihydrorhodamine 123 and supercoiled plasmid
DNA from oxidation mediated by peroxynitrous acid (ONOOH) [36,37]. This protec-
tive effect is attributed to radical-mediated oxidation of SeMet to its oxidized selenoxide
form SeMetO [38]. The reaction of SeMet with ONOOH follows a second-order rate con-
stant of k ~2.4 × 103 M−1s−1, which is almost tenfold higher than the one for Met at just
3.64 × 102 M−1s−1. Not surprisingly, SeMet therefore competes significantly with cellular
targets at similar concentrations [38,39]. The oxidation of SeMet to SeMetO is not lim-
ited to ONOOH, and an analogous reactivity has also been observed for other oxidants,
such as H2O2, the enzymatic monooxygenase system, amino acid-, peptide- and protein-
bound hydroperoxides, hypothiocyanous acid HOSCN and hypochlorite HOCl-derived
chloramines [40–42]. Moreover, a preference of hydroperoxides (ROOH) for SeMet over
Met and GSH has also been noticed, and these hydroperoxides produced in amino acids,
peptides and proteins tend to oxidize SeMet quite rapidly, as compared to the standard
oxidant H2O2 [43]. SeMet is therefore a good, albeit not outstanding, antioxidant and may
protect proteins against oxidative stress (OS) caused by a range of reactive oxygen species
(ROS).
Equally notably, SeMet itself is not only a small-molecule antioxidant, and its ability
to become part of proteins and enzymes in the position of Met enables SeMet to be present
when and where such oxidative damage may occur. In sharp contrast, the oxygen analog
of SeMet and Met, the amino acid methoxinine, is unable to hijack pathways designated for
Met, possibly because the oxygen atom is smaller than sulfur and selenium, albeit smaller
atoms usually are less demanding and more flexible in such situations. Regardless of the
deeper philosophical questions of why Se, and not O, may disguise itself as sulfur, the
implications of this Trojan Horse issue include the more or less random replacement of
Met by SeMet in proteins, such as human membrane protein B7-1. The glycoprotein B7-1
comprises six Met residues out of a total of 201 amino acids and SeMet has been reported to
replace 60% of these Met residues. In another human protein, angiopoietin-2 (Ang2), which
contains four Met residues out of a total of 215 amino acids, SeMet has been reported to
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replace 93% of Met. A similar trend has been reported for other human proteins, including
Tie2, netrin-1, plexinB3, ADAM10 and EphA3, where SeMet replaces more than 85% of the
Met residues [44–46].
This replacement does not go unnoticed, as the biological behavior of SeMet differs
from the one of Met. Although both chalcogens are redox active and may be oxidized
to sulfoxide (RS(O)R’) and selenoxide (RSe(O)R’), respectively, selenides and selenoxides
are usually more (re-)active. The selenide, for instance, is the far better reducing agent
and antioxidant compared to the sulfide, hence providing stronger antioxidant protection
for the protein containing SeMet in place of Met and also a direct protection for the
environment this protein is placed in, as shown in Figure 3. Interestingly, the oxidized form,
the selenoxide, is also more reactive compared to the sulfoxide and may react spontaneously
yet also selectively with thiol groups, such as the one in GSH. This enables the selenoxide
to redox (re-)cycle the selenide whilst producing GSSG and H2O, as depicted in Figure 3.
The ability of SeMet and thus also SeMet containing proteins to act as redox catalysts has
been corroborated recently by an in vitro study conducted by Caroll et al., in which the
oxidized form SeMetO has been reduced spontaneously by GSH to recycle SeMet, a process
subsequently coupled to energy metabolism via the reduction of oxidized glutathione
disulfide GSSG by glutathione reductase in the presence of NADPH with a second-order
rate constant k2 ranging from 103 to 104 M−1s−1. Apart from a spontaneous reduction of
SeMetO in the presence of GSH, it also looks as if thioredoxin reductase (TR) has the ability
to accept SeMetO as substrate, reducing SeMetO to SeMet [47].
Figure 3. SeMet in its reduced and oxidized forms is redox active and able to engage in catalytic detoxification of ROS, such
as H2O2. The resulting redox cycle consumes thiols and hence may change the cellular concentration of GSH and modulate
the cellular thiolstat. Please also note that neither sulfur in Met nor selenium in SeMet are overoxidized under physiological
conditions. Therefore, higher and quite interesting oxidation states, such as sulfones (RS(O)2R’) and selenones RSe(O)2R’)
are less common and more an object for ex vivo hypothetical studies (Pr = protein) [47].
It is therefore not surprising that proteins and enzymes loaded with SeMet exhibit
somewhat different and de facto additional properties compared to their unsubstituted
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analogs. In general, these proteins and enzymes are now also good and often catalytic
antioxidants, albeit not as strong as enzymes based on SeCys, such as GPx or human TR.
Taken together, the selenide/selenoxide redox pair therefore is a spontaneous redox
cycler and catalyst, while the sulfoxide itself is more or less inert and requires the assistance
of enzymes such as sulfoxide reductases MsrA or MsrB to get reduced to sulfide [48].
Please note that not every SeMet found in a plant, fungal or mammalian cell is
incorporated into proteins. In humans, dietary SeMet intake corresponds to the total
Se content in the blood. Here, SeMet is incorporated primarily by erythrocytes into
hemoglobin. In plasma, SeMet is found mostly in the albumin fraction. In humans, SeMet
is often associated with albumin. For example, SeMet concentrations of 28.3 and 53.4 ng/g
have been reported in individuals residing in a selenium-deficient region of China. This
concentration of SeMet corresponds to around 20% of the total selenium content in albumin.
In contrast, individuals residing in selenium-rich areas of China exhibited elevated levels
of SeMet, which constituted around 47.5% of the total selenium content in albumin [49].
5. Implications of SeMet in Aging and Diseases Related to OS
The high redox activity of SeMet has major physiological consequences, which can
be classified as the result of (a) SeMet as an antioxidant, (b) SeMet as a GPx-like redox
catalyst, (c) SeMet as a provider of selenium, (d) SeMet as an intermediate for a family of
RSeS and (e) SeMet as a substitute for Met in proteins and enzymes. In most instances,
a medley of these different aspects unique to this selenium amino acid is responsible for
the physiological activities recorded in practice. Here, the scope of biological activities of
SeMet is extremely broad, including simple selenium supplementation as a nutraceutical,
antioxidant, anti-inflammatory and preventive activities. As there are numerous reports on
such possible activities in the literature a few selected and rather interesting highlights of
such activities need to suffice as a part of this review, with relevant literature provided for
further information.
5.1. Selenomethionine Supplements Minimize Cardiac Dysfunction
The population above the age of 65 is more prone to suffer from cardiovascular
diseases which are occasionally associated with elevated levels of ROS [50]. The main
sources of intracellular ROS involve mitochondria which are found especially abundantly in
cardiac tissues. The dysregulation of mitochondrial functions and excessive ROS generation
may lead to pathologies, such as myocardial ischemia (MI) and myocardial reperfusion
(MR) [51]. In these cells, SeMet has been reported to act as an antioxidant able to scavenge
these harmful species and therefore to serve as an efficient cardio-protective agent [52].
In a regime of an open-label randomized clinical trial, 100 peripartum cardiomyopathy
(PPCM) patients with reduced left ventricular ejection fraction below 45% and reduced
total selenium levels below 70 µg/L were provided either with an oral supplement of
200 µg/day of SeMet for three months or a placebo, together with the recommended
therapy. The symptoms of heart failure were observed in 69% of the placebo group of
54 patients and in only 39% of the group of 46 patients supplemented by SeMet. A total
of 12 deaths from any cause were witnessed during this study, and among them, nine
belonged to the placebo group and only three to the supplemented group. Overall, SeMet
supplementation in this study therefore decreased the symptoms of heart failure and
general mortality [53].
5.2. SeMet Regulates Inflammatory Reactions in Atherosclerosis
Aging also interferes with atherogenesis via numerous pathways, and it is highly
unlikely that one specific factor dominates the overall pathophysiological mechanism. [54].
Aging is often accompanied by gradual modifications in the bone marrow, which not
only leads to enhanced clonal hematopoiesis of indeterminate potential (CHIP), it also
provokes alterations of myeloid cell differentiation, and both of these notorious processes
trigger atherosclerosis. The progression of CHIP-associated atherosclerosis is mediated
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by the signaling of IL-6 and activation of the inflammasome. Moreover, aging also leads
to a gradual reduction of mitochondrial function and elevated levels of interleukin-6
(IL-6) in the vasculature leading to atherosclerosis. Other factors triggering age-related
atherosclerosis include the vasculature and myeloid cells of the immune system which
activate the inflammatory pathways, especially IL-6 [54]. Literature demonstrates that
selenium is able to downregulate the levels of IL-6 [55,56]. Selenium supplementation
has been reported to prevent atherosclerosis by inhibiting OS, modulating inflammation,
suppressing endothelial dysfunction and protecting vascular cells against apoptosis and
calcification [57]. Furthermore, SeMet stimulates the immune response by reinforcing
the endogenous antioxidant defense systems comprising thioredoxin and GSH and by
directly scavenging harmful oxidant species. SeMet has also been reported to reduce the
formation of atherosclerotic plaques, provide a stable lesion phenotype and enhance the
function of vessels [58]. Furthermore, supplementation with SeMet significantly s reduces
the accumulation of inflammatory macrophages in lesions [58]. SeMet is also able to modify
the acute inflammatory response within a clinically relevant setting [58]. Indeed, these
latest developments signify the potentially favorable impact of SeMet supplementation as
a therapeutic nutraceutical against atherosclerosis.
5.3. SeMet and Viral Infections
Dietary selenium supplementation has been reported to significantly enhance the
host immunity against viruses [59]. The topic of a beneficial role of selenium against viral
infections has recently gained considerable attention due to the outbreak of COVID-19.
It has been reported that individuals residing in selenium-rich areas of China exhibit a
better rate of recovery from SARS-CoV-2 infections as compared to individuals residing
in selenium-deficient areas in the same country [60]. The deficiency of selenium is gen-
erally associated with elevated OS due to decreased detoxification of ROS resulting in
hyperinflammation in critically ill patients of COVID-19. Viral infections in general and
SARS-CoV-2 infections in particular are also characterized by elevated OS, which ulti-
mately results in immunopathological diseases. Selenium, being a multifunctional trace
element, enhances immunity, decreases OS, inhibits viral infections and provides efficient
support in healing the patients suffering from COVID-19 [61]. Furthermore, SeMet may
inhibit single-stranded RNA viruses, such as Coxsackie virus, hepatitis C virus (HCV)
and human immunodeficiency virus (HIV), at a concentration of 50 µM, as observed in
in vitro studies [62]. Moreover, SeMet has been reported to inhibit porcine circovirus type
2 (PCV2) in vitro in a concentration-dependent fashion between 2 and 16 µM. PCV2 is a
notorious single-stranded DNA virus associated with several complications, including
porcine dermatitis nephropathy syndrome (PDNS), postweaning multisystemic wasting
syndrome (PMWS), porcine respiratory disease complex (PRDC), congenital tremor type
A2 (CT) and pregnant sow reproductive obstruction [63–65]. The large differences in con-
centrations of SeMet required for antiviral activity in these studies against single-stranded
RNA and DNA viruses may denote some selectivity of this RSeS towards the later type of
viruses, albeit more studies are required to confirm this trend. Overall, SeMet may serve as
a multifunctional agent in the fight against viral infections by attacking components of the
virus, by serving as an antioxidant and redox modulator, by interfering with the cellular
thiolstat and by bolstering the immune system of the host.
5.4. SeMet and Cancer
Cancer is not only related to OS, it is also to some extent linked to aging [66]. The
prevalence of most cancers increases remarkably with age and cancer is the dominant cause
of death in both males and females above 60 years of age [67]. A study in 2018 has reported
a median age of 65 for the diagnosis of cancer and a median age of 74 for death due to
cancer [67,68]. This consistently increasing risk of developing a certain type of cancer with
age has been attributed to the gradual decrease in the microenvironment of many tissues,
which is essential for normal tissue maintenance and detoxification, a gradual shift of the
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balance between healthy and unhealthy cells towards unhealthy cells and a diminished
ability of the body to remove dysfunctional cells [66].
Because SeMet is able to counteract each of these changes, it may be beneficial in the
fight against cancer in several ways and via several avenues. As discussed already, SeMet
is a good antioxidant and may therefore prevent DNA damage. SeMet and its follow-
on products are also able to kill cancer cells. Indeed, SeMet is cleaved by the γ—lyase
methioninase and therefore produces CH3SeH, which in turn causes the oxidation of thiols
and generation of superoxide radical anions (O2•−). Together, these pro-oxidant actions
affect the cellular thiolstat and, especially under the conditions of sufficient OS, may also
cause apoptosis.
Not surprisingly, SeMet has been reported to inhibit different cancer cell lines, includ-
ing colorectal (SW-480), prostate (DU-145), breast (MCF-7/S) and melanoma (UACC-375)
cell lines [69,70]. In mice, SeMet also inhibits metastasis of breast cancer, while traditional
SeO32− supplementation in these studies has triggered extensive metastasis [71].
Notably, a variety of cancer cells depend on a sufficient supply of the amino acid Met,
a feature often referred to as the Hoffmann effect [72]. As SeMet is able to substitute for Met,
supplementation with SeMet may indeed suppress the uptake and action of Met, thereby
replacing the under these conditions less beneficial amino acid Met for the anticancer
actions associated with SeMet. If and how such a replacement of Met for the Trojan redox
Horse SeMet may be implemented in practice is speculative although worth following with
relevant studies.
6. Conclusions
Our brief and necessarily incomplete overview of the biochemistry and possible
preventive and therapeutic roles of the second selenium amino acid SeMet has shown that
this amino acid is as colorful as its more popular relative SeCys. SeMet is produced in
plants and certain mushrooms and may also be taken up and processed in mammals and
humans. SeMet is not only an excellent supplier of the trace element selenium; it is also
redox active and may act as redox catalyst inside cells. Notably, SeMet is very similar to
its sulfur analog Met and often uses the cellular pathways of Met, a red herring to allow
SeMet to enter a range of sulfur proteins. Evidence for the health benefits of SeMet, for
instance, as a selenium-containing food supplement, is therefore mounting, and there
are early reports on possible roles in age-related human diseases, such as cardiovascular
diseases and atherosclerosis and also during viral infections. The roles of SeMet as the
22nd proteogenic human amino acid are therefore definitely worth more research.
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